Investor & Media Relations

We discover and develop medicines to defeat neurodegeneration.

The science is breaking open and the time is right for an ambitious and rigorous effort to address Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. We are applying deep scientific and drug development expertise to discover effective molecular therapeutics and have engineered a proprietary technology to deliver biologic therapeutics to the brain.

With a team of experienced and passionately dedicated scientists and drug developers, we believe we can succeed in meaningfully improving the lives of patients and their families.

Denali Nasdaq

Press Releases

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 27, 2024

Read More
Denali Therapeutics Announces $500 million Private Placement Equity Financing

Feb 27, 2024

Read More
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Feb 07, 2024

Read More



Feb 7 - Feb 8, 2024 5:00 PM PST


Corporate Presentation

  • Change

  • Volume

  • Market Cap

  • Today's Open

  • Previous Close

  • Exchange


  • Today's High

  • Today's Low

  • 52 Week High

  • 52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Analyst Coverage

View detailed list of firms and analysts.

View Coverage

SEC Filing

View, download, and share all SEC Filing documents.

View Documents

Corporate Governance

View, download, and share Corporate Governance documents.

View Documents